HAMBURG, Germany, Jan. 13, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec. The milestone reached was on the transition of an oncology programme into lead optimisation.
